Biblio
Weight-adjusted urinary creatinine excretion predicts transplant outcomes in adult patients with acute myeloid leukemia in complete remission. Leuk Lymphoma. 2022:1-11.
[Tyrosine kinase inhibitor maintenance therapy following allogenic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia]. Rinsho Ketsueki. 2020;61(1):11-19.
[Ruptured mycotic cerebral aneurysm in an adult T-cell leukemia/lymphoma patient undergoing allogeneic stem cell transplantation]. Rinsho Ketsueki. 2024;65(2):84-89.
Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia W. Bone Marrow Transplant. 2020.
Recurrent DDX41 mutation in very late relapse after allogeneic stem cell transplantation. Leukemia. 2024.
Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol. 2014.
. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant]. Rinsho Ketsueki. 2023;64(7):586-595.
Overcoming relapse: prophylactic or pre-emptive use of azacitidine or FLT3 inhibitors after allogeneic transplantation for AML or MDS. Int J Hematol. 2023.
. Outcomes of cessation of the administration of nucleos(t)ide analogues on HBV reactivation after allogeneic hematopoietic stem cell transplantation: A nationwide retrospective study. Transplant Cell Ther. 2024.
Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study. Leuk Res. 2021;108:106627.
Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. Cancer Sci. 2023.
MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations. Int J Hematol. 2021.
Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation. Br J Haematol. 2023.
[Kidney transplantation for end-stage renal disease after third allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia]. Rinsho Ketsueki. 2024;65(1):7-12.
Induction of WT1 specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/Il2rgKO mice. Blood. 2015.
Identification of compounds that preferentially suppress the growth of T-cell acute lymphoblastic leukemia-derived cells. Cancer Sci. 2023.
[FLT3-ITD mutation-positive acute myeloid leukemia undergoing clonal transition with PTPN11 mutation at relapse]. Rinsho Ketsueki. 2024;65(2):63-68.
The emergence of rare nocardiosis following allogeneic hematopoietic stem cell transplantation in the era of molecular taxonomy. Int J Infect Dis. 2019.
Elevation of urinary liver-type fatty acid-binding protein is a harbinger of poor patient prognosis after allogeneic stem cell transplantation. Transplant Cell Ther. 2023.
Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. Acta Haematol. 2019;141(2):111-118.
Different effects of thymoglobulin on acute leukemia with pre-transplant residual blasts in HLA mismatch transplantation. Int J Hematol. 2023.
Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated BMT and single unit CBT in adults with acute leukemia. Biol Blood Marrow Transplant. 2015.
Chimeric antigen receptor T-cell therapy following autologous transplantation for secondary central nervous system lymphoma: A case report. Medicine (Baltimore). 2021;100(44):e27733.